| Literature DB >> 33112451 |
Claudia Lehner1,2, Alina Hubbuch2,3, Kira Schmitt3,4, Gertraud Schuepbach-Regula5, Barbara Willi3, Meike Mevissen6, Ruth Peter2, Cedric R Muentener2, Hanspeter Naegeli2, Simone Schuller1.
Abstract
BACKGROUND: Antimicrobial stewardship programs (ASPs) are important tools to foster prudent antimicrobial use.Entities:
Keywords: antibiotic; antimicrobial resistance; dog; guidelines; prescribing habits
Mesh:
Substances:
Year: 2020 PMID: 33112451 PMCID: PMC7694852 DOI: 10.1111/jvim.15906
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
Inclusion and exclusion criteria and search terms for the surveyed indications
| Indication | Included | Excluded | Search terms |
|---|---|---|---|
| Acute diarrhea |
Diarrhea <3 wk Acute hemorrhagic diarrhea syndrome (AHDS) Parasitic diarrhea Nonspecific diarrhea |
Diarrhea >3 wk or relapsing Diarrhea related to drug administration or another extradigestive disease Diarrhea that started during hospitalization Parvovirosis | Diarrhea, colitis, duodenitis, enteritis, ileitis, gastritis, AHDS, hemorrhagic gastro‐enteritis, Giardia, watery feces |
| Urinary tract infection |
Suspicion or diagnosis of bacterial cystitis Suspicion or diagnosis of pyelonephritis |
Glomerulonephritis Leptospirosis Urolithiasis without signs of bacteriuria | Urinary tract infection, dysuria, difficult urination, stranguria, hematuria, bloody urine, blood in urine, polyuria, pollakiuria, pyelonephritis, inflammation of the bladder, cystitis, bladder, urinalysis |
| Respiratory tract infection |
Aspiration pneumonia Pneumonia (bacterial, viral, unknown) Bronchitis Kennel cough |
Nasal infections Fungal infections Neoplasia of the respiratory tract Lung worms | Respiratory tract infection, respiratory tract disease, cough, tracheitis, tracheobronchitis, pneumonia, inflammation of the lungs, bronchitis, bronchopneumonia, kennel cough, distemper, influenza, adenovirus, dyspnea, tachypnea |
| Wound infection |
Bite wound Abscess |
Anal gland abscess Dental abscess Abscess because of a foreign body Hot‐spot | Wound infection, abscess, purulent wound, bite |
Criteria used to judge appropriate use of antimicrobials based on national and international recommendations , , ,
| Indication | Comment | Antimicrobial | Dosage (mg/kg) | Application frequency | Treatment duration (days) |
|---|---|---|---|---|---|
| Acute diarrhea | Antimicrobial treatment NOT indicated unless suspicion of sepsis based on clinical and clinicopathologic data |
Ampicillin Amoxicillin Amoxicillin/Clavulanic acid Ampicillin/Sulbactam |
20 11‐15 12.5‐20 30 |
q12h/q8h q12h/q8h q12h/q8h q12h/q8h |
5‐7 5‐7 5‐7 5‐7 |
| If suspicion of sepsis |
Enrofloxacin OR Marbofloxacin AND/OR Metronidazole |
10‐20 2 15 |
q24h q24h q24h |
5‐7 5‐7 5‐7 | |
| Urinary tract infections |
Antimicrobial treatment only indicated if bacteriuria was confirmed by sediment or culture of urine collected via cystocentesis. In previous guidelines, complicated UTI were defined as infections that occur in the presence of an anatomic or functional abnormality or a comorbidity that predisposes the patient to persistent infection, recurrent infection, or treatment failure. |
Amoxicillin Ampicillin |
11‐15 20 |
q12h/q8h q12h/q8h |
5‐7 5‐7 |
|
Amoxicillin Amoxicillin/Clavulanic acid Ampicillin Ampicillin/Sulbactam Trimethoprim/Sulfadiazin Trimethoprim/Sulfamethoxazole |
11‐15 12.5‐20 20 30 15 15 |
q12h/q8h q12h/q8h q12h/q8h q12h/q8h q12h q12h |
5‐28 5‐28 5‐28 5‐28 5‐28 5‐28 | ||
|
Enrofloxacin Marbofloxacin |
10‐20 2 |
q24h q24h |
5‐42 5‐42 | ||
|
Amoxicillin/Clavulanic acid Ampicillin/Sulbactam Enrofloxacin Marbofloxacin |
12.5‐20 30 10‐20 2 |
q12h/q8h q12h/q8h q24h q24h |
5‐42 5‐42 5‐42 5‐42 | ||
| Respiratory tract infections | Aspiration pneumonia or bacterial bronchopneumonia |
Doxycycline Amoxicillin/Clavulanic acid Ampicillin/Sulbactam |
10 12.5‐20 30 |
q24h q12h/q8h q12h/q8h | Treatment 1 week beyond resolution of clinical/radiographic signs |
|
Amoxicillin/Clavulanic acid OR Ampicillin/Sulbactam AND Enrofloxacin OR Marbofloxacin |
12.5‐20 30 10‐20 2 |
q12h/q8h q12h/q8h q24h q24h | |||
|
| Doxycycline |
10 or 5 |
q24h q12h | 5‐14 | |
| Wound infections |
|
Amoxicillin/Clavulanic acid Cefalexin Clindamycin |
12.5‐20 20‐35 10‐15 |
q12h q12h/q8h q12h |
Abscesses or superficial Deep |
Abbreviation: UTI, urinary tract infection.
Sepsis criteria: lethargy plus at least 1 of the following: body temperature >39.4°C, heart rate >140/min, WBC <4 or >25 × 109/L, banded neutrophils >1.5 × 109/L.
IV or SC.
IV.
Treatment as listed for complicated UTI also judged appropriate.
Severe clinical, laboratory or radiographic signs.
Only skin damaged.
Skin and deeper structures damaged.
Modified justification score used to judge the accordance of antimicrobial prescriptions in dogs
| Justification score | Criteria |
|---|---|
| JS‐1 | Empirical prescription in accordance with international recommendations, that is, correct indication, antimicrobial class, dosage and treatment durationOR correct prescription according to culture and sensitivity profileOR no antibiotic indicated, and none prescribed |
| JS‐2 | Dosage and/or duration of prescription not in accordance with guidelines |
| JS‐3 | Antimicrobial class not in accordance with guidelines |
| JS‐4 | Decision to treat in complete disagreement with guidelines, that is, antibiotic prescription when not indicated or no antibiotic prescription although indicated |
Abbreviation: JS, justification score.
Characteristics of dogs presented with the indicated diseases in 2016 or 2018
| Parameter | Acute diarrhea | Urinary tract infections | Respiratory tract infections | Bite wounds/abscesses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 | 2018 |
| 2016 | 2018 |
| 2016 | 2018 |
| 2016 | 2018 |
| |
| Total | 371 | 408 | .64 | 245 | 260 | .91 | 274 | 306 | .55 | 175 | 166 | .23 |
| Sex | .19 | .67 | .78 | .05 | ||||||||
| Female | 173 | 178 | 151 | 160 | 129 | 134 | 91 | 71 | ||||
| Male | 193 | 223 | 92 | 99 | 143 | 169 | 81 | 86 | ||||
| Unknown | 5 | 7 | 2 | 1 | 2 | 3 | 3 | 9 | ||||
| Age (years) Median (IQR | 5 (1‐9) | 5 (2‐9) | .69 | 9 (5‐11) | 9 (4‐12) | .16 | 6 (2‐11) | 7 (2‐11) | .60 | 6 (3‐9) | 7 (3‐10) | .14 |
| Breed | .20 | .84 | .36 | .22 | ||||||||
| Purebred | 305 | 317 | 194 | 200 | 226 | 248 | 133 | 121 | ||||
| Mixed breed | 60 | 86 | 47 | 56 | 42 | 55 | 40 | 38 | ||||
| Unknown | 6 | 5 | 4 | 4 | 6 | 3 | 2 | 7 | ||||
Interquartile range.
FIGURE 1Most commonly used antimicrobial classes in 2016 and 2018. *P < .001; **P = .001; other antimicrobial classes were each used in less than 2% of all cases and are therefore not shown
FIGURE 2Proportions of justification scores in 2016 and 2018
Antimicrobial prescriptions and justification scores for acute diarrhea in 2016 and 2018 in university hospitals and private practices
| University hospitals | Private practices | |||||
|---|---|---|---|---|---|---|
| 2016 | 2018 |
| 2016 | 2018 |
| |
| Total number of cases | 165 | 197 | 206 | 211 | ||
| Dogs prescribed antimicrobials | 116 (70%) | 80 (41%) |
| 127 (62%) | 90 (43%) |
|
|
Antimicrobial classes prescribed Nitroimidazole Potentiated aminopenicillin Fluoroquinolone First generation cephalosporin Aminopenicillin Third generation cephalosporin Tetracycline Potentiated sulfonamide |
74 (64%) 55 (47%) 3 (3%) 0 (0%) — — — — |
22 (28%) 70 (88%) 18 (23%) 1 (1%) — — — — |
.23 — — — — |
100 (79%) 13 (10%) 15 (12%) — 9 (7%) 3 (2%) 3 (2%) 0 (0%) |
74 (82%) 10 (11%) 6 (7%) — 8 (9%) 0 (0%) 0 (0%) 4 (4%) |
.53 .84 .21 — .63 .14 .14 .02 |
| At least 1 HPCIA prescribed | 3 (3%) | 18 (23%) |
| 18 (14%) | 6 (7%) | .08 |
| Combination treatment | 11 (10%) | 24 (30%) |
| 6 (5%) | 6 (7%) | .54 |
| Duration (d) Median (IQR) | 9 (7‐11.5) | 6 (5‐10) |
| 7 (5‐9) | 6 (5‐9) | .76 |
| At least minimal work‐up | 131 (79%) | 178 (90%) |
| 16 (8%) | 18 (9%) | .78 |
|
JS 1 2 3 4 Judgment not possible |
56 (34%) 5 (3%) 15 (9%) 88 (53%) 1 (.6%) |
120 (61%) 5 (3%) 14 (7%) 56 (28%) 2 (1%) |
.78 .49
.67 |
62 (30%) 0 (0%) 3 (2%) 102 (50%) 39 (19%) |
80 (38%) 0 (0%) 3 (1%) 62 (29%) 66 (31%) |
.09 — .98
.004 |
Note: Bonferroni corrected P‐value for significance ≤.003.
Abbreviations: HPCIA, highest priority critically important antimicrobial; JS, justification score.
CBC.
Antimicrobial prescriptions, diagnostic work‐up and justification scores for urinary tract infections in 2016 and 2018 in university hospitals and private practices
| University hospitals | Private practices | |||||
|---|---|---|---|---|---|---|
| 2016 | 2018 |
| 2016 | 2018 |
| |
| Total number of cases | 70 | 96 | 175 | 164 | ||
| Dogs prescribed antimicrobials | 68 (97%) | 88 (91%) | .14 | 147 (84%) | 125 (76%) | .07 |
|
Antimicrobial classes prescribed Potentiated aminopenicillin Fluoroquinolone Aminopenicillin First generation cephalosporin Lincosamide Potentiated sulfonamide Amphenicol Aminoglycoside Tetracycline Third generation cephalosporin |
53 (78%) 12 (18%) 5 (7%) 2 (3%) 2 (3%) 1 (2%) 1 (2%) 0 (0%) 0 (0%) — |
64 (73%) 23 (26%) 4 (5%) 1 (1%) 0 (0%) 2 (2%) 0 (0%) 2 (2%) 1 (1%) — |
.46 .21 .46 .42 .11 .72 .25 .21 .38 — |
97 (66%) 43 (29%) 22 (15%) 11 (8%) — — — — 0 (0%) 3 (2%) |
100 (80%) 17 (14%) 31 (25%) 5 (4%) — — — — 1 (.8%) 1 (.8%) |
.01
.04 .22 — — — — .28 .40 |
| At least 1 HPCIA prescribed | 12 (18%) | 25 (28%) | .12 | 46 (31%) | 18 (14%) |
|
| Combination treatment | 5 (7%) | 3 (3%) | .27 | 0 (0%) | 4 (3%) | .03 |
| Duration (d) Median (IQR) | 21 (10‐27.5) | 15 (10‐28) | .43 | 10 (8‐14) | 10 (7‐14) | .40 |
| Culture performed | 67 (96%) | 91 (95%) | .78 | 43 (25%) | 31 (19%) | .21 |
| Microscopic sediment analysis performed | 59 (84%) | 77 (80%) | .50 | 73 (42%) | 75 (46%) | .77 |
| Bacterial etiology confirmed | 62 (89%) | 85 (89%) | 1 | 27 (15%) | 26 (16%) | .91 |
|
JS 1 2 3 4 Judgment not possible |
38 (54%) 4 (6%) 13 (19%) 14 (20%) 1 (1%) |
49 (51%) 8 (8%) 22 (23%) 14 (15%) 3 (3%) |
.68 .52 .50 .36 .48 |
11 (6%) 1 (.6%) 17 (10%) 25 (14%) 121 (69%) |
15 (9%) 2 (1%) 10 (6%) 21 (13%) 116 (71%) |
.32 .52 .22 .69 .75 |
Note: Bonferroni corrected P‐value for significance ≤.002.
Abbreviations: HPCIA, highest priority critically important antimicrobial; JS, justification score.
Antimicrobial prescriptions, diagnostic work‐up and justification scores for respiratory tract infections in 2016 and 2018 in university hospitals and private practices
| University hospitals | Private practices | |||||
|---|---|---|---|---|---|---|
| 2016 | 2018 |
| 2016 | 2018 |
| |
| Total number of cases | 108 | 125 | 166 | 181 | ||
| Dogs prescribed antimicrobials | 82 (76%) | 83 (66%) | .11 | 89 (54%) | 56 (31%) |
|
|
Antimicrobial classes prescribed Potentiated aminopenicillin Fluoroquinolone Tetracycline First generation cephalosporin Aminopenicillin Nitroimidazole Macrolide Third generation cephalosporin Penicillin Amphenicol |
59 (72%) 23 (28%) 12 (15%) 4 (5%) 2 (2%) 1 (1%) 1 (1%) 1(1%) — — |
71 (86%) 27 (33%) 12 (15%) 1 (1%) 0 (0%) 5 (6%) 0 (0%) 0 (0%) — — |
.03 .53 .97 .17 .15 .10 .31 .31 — — |
58 (65%) 4 (5%) 26 (29%) 0 (0%) 33 (37%) — — 3 (3%) 0 (0%) 0 (0%) |
34 (61%) 4 (7%) 15 (27%) 1 (2%) 16 (29%) — — 1 (2%) 1 (2%) 1 (2%) |
.59 .50 .75 .21 .29 — — .57 .21 .21 |
| At least 1 HPCIA prescribed | 25 (31%) | 27 (33%) | .78 | 7 (8%) | 5 (9%) | .82 |
| Combination treatment | 18 (22%) | 23 (28%) | .39 | 4 (5%) | 1 (2%) | .38 |
| Duration (d) Median (IQR) | 14 (10‐21) | 15 (8‐28) | .32 | 9 (6.5‐11) | 8 (7‐10) | .44 |
| Clinical exam only | 6 (6%) | 3 (2%) | .21 | 145 (87%) | 155 (86%) | .64 |
| At least minimal work‐up | 75 (69%) | 101 (81%) | .04 | 1 (.6%) | 3 (2%) | .36 |
| BAL and culture performed | 8 (7%) | 4 (3%) | .15 | 2 (1%) | 0 (0%) | .14 |
|
JS 1 2 3 4 Judgment not possible |
68 (63%) 1 (.9%) 15 (14%) 19 (18%) 5 (5%) |
75 (60%) 7 (6%) 14 (11%) 8 (6%) 21 (17%) |
.64 .05 .54 .008 .003 |
64 (39%) 3 (2%) 11 (7%) 45 (27%) 43 (26%) |
76 (42%) 1 (.6%) 10 (6%) 15 (8%) 79 (44%) |
.58 .27 .67
|
Note: Bonferroni corrected p‐value for significance ≤.002.
Abbreviations: BAL, bronchoalveolar lavage; HPCIA, highest priority critically important antimicrobial; JS, justification score.
Thoracic radiographs and CBC.
Antimicrobial prescriptions and justifications scores for abscesses and bite wounds in 2016 and 2018 in private practices
| 2016 | 2018 |
| |
|---|---|---|---|
| Total number of cases | 175 | 166 | |
| Dogs prescribed antimicrobials | 157 (90%) | 147 (89%) | .73 |
|
Antimicrobial classes prescribed Potentiated aminopenicillin Aminopenicillin First generation cephalosporin Fluoroquinolone Third generation cephalosporin Lincosamide Nitroimidazole |
132 (84%) 54 (34%) 18 (12%) 5 (3%) 2 (1%) 1 (.6%) 0 (0%) |
117 (80%) 45 (31%) 23 (16%) 4 (3%) 1 (.7%) 4 (3%) 1 (.7%) |
.31 .48 .29 .81 .60 .15 .30 |
| At least 1 HPCIA prescribed | 7 (5%) | 5 (3%) | .64 |
| Combination therapy | 3 (2%) | 6 (4%) | .26 |
| Duration (d) Median (IQR) | 7 (6‐10) | 8 (7‐11) | .13 |
| Local wound treatment | 113 (65%) | 124 (75%) | .04 |
| Drain placement | 14 (8%) | 27 (16%) | .02 |
|
JS 1 2 3 4 Judgment not possible |
105 (60%) 26 (15%) 6 (3%) 28 (16%) 10 (6%) |
78 (47%) 22 (13%) 10 (6%) 20 (12%) 36 (22%) |
.02 .67 .26 .29
|
Note: Bonferroni corrected P‐value for significance ≤.003.
Abbreviations: HPCIA, highest priority critically important antimicrobial; JS, justification score.